Company intelligence / Profile preview
Da Volterra
Paris, Île-de-France, Francedavolterra.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Da Volterra developed DAV132, a product that protects intestinal microbiota from antibiotic-induced disruption. It was tested in four clinical trials with 284 human volunteers and demonstrated proof of concept for protection against antibiotic dysbiosis. The company declared bankruptcy on December 2, 2022.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Live biotherapeutic productsEnzymeAdsorbent technology
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
European Union Seventh FrameworkBPIFranceEU Innovative Medicines Initiative (IMI)
Beyond the preview
Go deeper on Da Volterra.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Da Volterra.